Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case report

Abstract Background Reports of autoimmune diseases coexisting with autoimmune pulmonary alveolar proteinosis (autoimmune PAP; APAP) are extremely rare. APAP coexisting with autoimmune diseases may often be misdiagnosed as connective tissue disease–associated interstitial lung disease (ILD). Here, we...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomoki Kozono, Kentaro Tanaka, Tomoko Yagi, Kazuto Kamikawaji, Masaki Watanabe, Azusa Iwanaga, Minako Hamada, Yoshifusa Koreeda, Hiromasa Inoue, Ikkou Higashimoto
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Pulmonary Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12890-025-03489-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832586047829049344
author Tomoki Kozono
Kentaro Tanaka
Tomoko Yagi
Kazuto Kamikawaji
Masaki Watanabe
Azusa Iwanaga
Minako Hamada
Yoshifusa Koreeda
Hiromasa Inoue
Ikkou Higashimoto
author_facet Tomoki Kozono
Kentaro Tanaka
Tomoko Yagi
Kazuto Kamikawaji
Masaki Watanabe
Azusa Iwanaga
Minako Hamada
Yoshifusa Koreeda
Hiromasa Inoue
Ikkou Higashimoto
author_sort Tomoki Kozono
collection DOAJ
description Abstract Background Reports of autoimmune diseases coexisting with autoimmune pulmonary alveolar proteinosis (autoimmune PAP; APAP) are extremely rare. APAP coexisting with autoimmune diseases may often be misdiagnosed as connective tissue disease–associated interstitial lung disease (ILD). Here, we describe a rare case of a patient with systemic sclerosis who was diagnosed with APAP after the exacerbation of lung opacities during treatment with immunosuppressive agents. Case presentation A 72-year-old woman was diagnosed with systemic sclerosis (SSc) at the age of 68, and initiated treatment with prednisolone (PSL). At the age of 70, she was diagnosed with ILD associated with SSc. Despite intravenous cyclophosphamide (IVCY), no improvement was observed. A significant elevation of Krebs von den Lungen-6 (KL-6) and a crazy-paving pattern on chest computed tomography (CT) are observed. Bronchoscopy showed milky white bronchoalveolar lavage fluid (BALF) and histology of periodic acid-Schiff (PAS) stain-positive eosinophilic granular material. Serum anti granulocyte–macrophage colony-stimulating factor (GM-CSF) antibodies were measured, and the result was positive, leading to the diagnosis of APAP. Conclusion In patients with interstitial lung shadows who do not improve with immunosuppressive treatment, PAP is one of the differential diagnoses that should be considered. All physicians should be aware that the appropriate diagnosis of PAP and the measurement of serum anti-GM-CSF antibodies will critically affect patient outcomes.
format Article
id doaj-art-3cba159167674524a9b02cc4027fd626
institution Kabale University
issn 1471-2466
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series BMC Pulmonary Medicine
spelling doaj-art-3cba159167674524a9b02cc4027fd6262025-01-26T12:13:07ZengBMCBMC Pulmonary Medicine1471-24662025-01-012511610.1186/s12890-025-03489-0Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case reportTomoki Kozono0Kentaro Tanaka1Tomoko Yagi2Kazuto Kamikawaji3Masaki Watanabe4Azusa Iwanaga5Minako Hamada6Yoshifusa Koreeda7Hiromasa Inoue8Ikkou Higashimoto9Department of Pulmonary Medicine, National Hospital Organization MinamiKyushu HospitalDepartment of Pulmonary Medicine Graduate School of Medical and Dental Sciences, Kagoshima UniversityDepartment of Pulmonary Medicine, National Hospital Organization MinamiKyushu HospitalDepartment of Pulmonary Medicine, National Hospital Organization MinamiKyushu HospitalDepartment of Pulmonary Medicine, National Hospital Organization MinamiKyushu HospitalDepartment of Pulmonary Medicine, National Hospital Organization MinamiKyushu HospitalDepartment of Pulmonary Medicine, National Hospital Organization MinamiKyushu HospitalDepartment of Pulmonary Medicine, National Hospital Organization MinamiKyushu HospitalDepartment of Pulmonary Medicine Graduate School of Medical and Dental Sciences, Kagoshima UniversityDepartment of Pulmonary Medicine, National Hospital Organization MinamiKyushu HospitalAbstract Background Reports of autoimmune diseases coexisting with autoimmune pulmonary alveolar proteinosis (autoimmune PAP; APAP) are extremely rare. APAP coexisting with autoimmune diseases may often be misdiagnosed as connective tissue disease–associated interstitial lung disease (ILD). Here, we describe a rare case of a patient with systemic sclerosis who was diagnosed with APAP after the exacerbation of lung opacities during treatment with immunosuppressive agents. Case presentation A 72-year-old woman was diagnosed with systemic sclerosis (SSc) at the age of 68, and initiated treatment with prednisolone (PSL). At the age of 70, she was diagnosed with ILD associated with SSc. Despite intravenous cyclophosphamide (IVCY), no improvement was observed. A significant elevation of Krebs von den Lungen-6 (KL-6) and a crazy-paving pattern on chest computed tomography (CT) are observed. Bronchoscopy showed milky white bronchoalveolar lavage fluid (BALF) and histology of periodic acid-Schiff (PAS) stain-positive eosinophilic granular material. Serum anti granulocyte–macrophage colony-stimulating factor (GM-CSF) antibodies were measured, and the result was positive, leading to the diagnosis of APAP. Conclusion In patients with interstitial lung shadows who do not improve with immunosuppressive treatment, PAP is one of the differential diagnoses that should be considered. All physicians should be aware that the appropriate diagnosis of PAP and the measurement of serum anti-GM-CSF antibodies will critically affect patient outcomes.https://doi.org/10.1186/s12890-025-03489-0Autoimmune pulmonary alveolar proteinosisAutoimmune diseasesSargramostim inhalationAnti-GM-CSF antibodies
spellingShingle Tomoki Kozono
Kentaro Tanaka
Tomoko Yagi
Kazuto Kamikawaji
Masaki Watanabe
Azusa Iwanaga
Minako Hamada
Yoshifusa Koreeda
Hiromasa Inoue
Ikkou Higashimoto
Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case report
BMC Pulmonary Medicine
Autoimmune pulmonary alveolar proteinosis
Autoimmune diseases
Sargramostim inhalation
Anti-GM-CSF antibodies
title Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case report
title_full Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case report
title_fullStr Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case report
title_full_unstemmed Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case report
title_short Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case report
title_sort autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis a case report
topic Autoimmune pulmonary alveolar proteinosis
Autoimmune diseases
Sargramostim inhalation
Anti-GM-CSF antibodies
url https://doi.org/10.1186/s12890-025-03489-0
work_keys_str_mv AT tomokikozono autoimmunepulmonaryalveolarproteinosisdevelopedduringtreatmentforsystemicsclerosisacasereport
AT kentarotanaka autoimmunepulmonaryalveolarproteinosisdevelopedduringtreatmentforsystemicsclerosisacasereport
AT tomokoyagi autoimmunepulmonaryalveolarproteinosisdevelopedduringtreatmentforsystemicsclerosisacasereport
AT kazutokamikawaji autoimmunepulmonaryalveolarproteinosisdevelopedduringtreatmentforsystemicsclerosisacasereport
AT masakiwatanabe autoimmunepulmonaryalveolarproteinosisdevelopedduringtreatmentforsystemicsclerosisacasereport
AT azusaiwanaga autoimmunepulmonaryalveolarproteinosisdevelopedduringtreatmentforsystemicsclerosisacasereport
AT minakohamada autoimmunepulmonaryalveolarproteinosisdevelopedduringtreatmentforsystemicsclerosisacasereport
AT yoshifusakoreeda autoimmunepulmonaryalveolarproteinosisdevelopedduringtreatmentforsystemicsclerosisacasereport
AT hiromasainoue autoimmunepulmonaryalveolarproteinosisdevelopedduringtreatmentforsystemicsclerosisacasereport
AT ikkouhigashimoto autoimmunepulmonaryalveolarproteinosisdevelopedduringtreatmentforsystemicsclerosisacasereport